Dr. Jack Gladstein, MD
Child Neurology (Neurology with Special Qualifications in Child Neurology Physician)
22 S Greene St
Baltimore, MD 21201
Who else practices at this address →
Baltimore city includes primary care (36% of residents) shortage areas. About shortage areas
At a glance
- Medical school
- Albert Einstein College of Medicine of Yeshiva University (1983)
- Years since graduation
- 43
- In the NPI registry since
- 2006
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1983Medical school: Albert Einstein College of Medicine of Yeshiva University
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology with Special Qualifications in Child Neurology Physician primary
MD license D34944 -
Pediatric Adolescent Medicine Physician
MD license D34944 -
Pediatrics Physician
MD license D34944
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- University of Maryland Pediatric Associates, PA (55 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Payments from drug and device companies
In 2025, 3 companies reported 3 payments worth $57.10 in total to this clinician.
| Kyowa Kirin, Inc. | $20.99 |
|---|---|
| Cmp Pharma, Inc. | $19.28 |
| Neurelis, Inc. | $16.83 |
| Food and Beverage | $57.10 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 3 companies. The companies reported $39,257 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Chronic Migraine (OAS…
Amgen Inc. - A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Episodic Migraine (OA…
Amgen Inc. - A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine
H. Lundbeck A S · Recruiting · NCT04965675 - A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
H. Lundbeck A S · Recruiting · NCT05164172 - A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
H. Lundbeck A S · Recruiting · NCT05897320 - A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatm…
Teva Pharmaceuticals USA, Inc. - A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pedia…
Teva Pharmaceuticals USA, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.